Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016', provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics. 

The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) 
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Overview 8
Therapeutics Development 9
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Stage of Development 9
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Therapy Area 10
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Indication 11
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Companies 15
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Universities/Institutes 18
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development 27
Bionomics Limited 27
Catalyst Biosciences, Inc. 28
CoMentis, Inc. 29
Johnson & Johnson 30
Merck & Co., Inc. 31
NeuroDerm Ltd. 32
Saniona AB 33
SK Biopharmaceuticals Co., Ltd. 34
Sunovion Pharmaceuticals Inc. 35
Vanda Pharmaceuticals Inc. 36
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles 37
(nicotine + opipramol hydrochloride) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
AN-761 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AQW-051 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AVL-3288 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
AVL-8168 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BNC-210 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BNC-375 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
DSP-3748 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Gln-1062 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
GTS-21 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
JNJ-39393406 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
NBP-14 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
SKLA-4R - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer's Disease and Schizophrenia - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TC-7020 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Projects 63
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products 67
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Featured News & Press Releases 68
Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder 68
Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP 69
Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder 70
Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial 70
Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210 71
Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression 72
Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 73
Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210 74
Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting 74
Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials 75
Sep 09, 2014: Positive Phase 1a Outcome for Memogain 77
Feb 21, 2014: Neurodyn creates Memogain Advisory Board 77
Jan 13, 2014: Neurodyn completes Part I of Memogain Phase IA Clinical Trial 78
Sep 27, 2013: Bionomics To Present BNC-375 At COGNITO Neuroscience Meeting 80
Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Bionomics Limited, H2 2016 27
Pipeline by Catalyst Biosciences, Inc., H2 2016 28
Pipeline by CoMentis, Inc., H2 2016 29
Pipeline by Johnson & Johnson, H2 2016 30
Pipeline by Merck & Co., Inc., H2 2016 31
Pipeline by NeuroDerm Ltd., H2 2016 32
Pipeline by Saniona AB, H2 2016 33
Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 34
Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 35
Pipeline by Vanda Pharmaceuticals Inc., H2 2016 36
Dormant Projects, H2 2016 63
Dormant Projects (Contd..1), H2 2016 64
Dormant Projects (Contd..2), H2 2016 65
Dormant Projects (Contd..3), H2 2016 66
Discontinued Products, H2 2016 67